Business Wire

EUROSETS

17.7.2024 11:13:26 CEST | Business Wire | Press release

Share
Eurosets: Newborn baby saved from acute bronchiolitis in Martinique by Colibri third-generation life-support device

The baby was affected by a viral infection, leaving him unable to breathe. Thanks to a state-of-the-art device, used for the first time in the world in the Caribbean, the medical-surgical team was able to save the infant.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716825866/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Colibrì, the lightest life-saving device that replaces the function of the heart and lungs (Photo: Eurosets)

The Colibri (hummingbird), one of the national symbols of Martinique, is also the name of an innovative, next-generation ECMO system, designed and manufactured by Eurosets, an Italian company based in the biomedical district of Medolla (MO), which enabled the medical-surgical team at Martinique University Hospital to save the life of a one-and-a-half-month-old child suffering from acute bronchiolitis.
The baby was born in Guadeloupe and weighed just 5kg. He was unable to breathe independently due to the viral infection, which subsequently led to heart failure. The infant was immediately transferred to the CHU de Martinique (CHUM), the only French hospital in the Caribbean with a third-level pediatric intensive care unit but, due the child's unstable condition, it was impossible to move him.
Following first-rate coordination with the neonatal intensive care unit at Guadeloupe University Hospital, the Martinique team from the UMAC (Unité Mobile d'Assistance Circulatoire) was able to travel to the neighboring island and connect the new ECMO system in the jugulo-carotid position to the newborn, allowing the infant to be transferred safely by helicopter.
The procedure was a success thanks to the seamless cooperation between Dr Xavier Beretta-Piccoli, pediatric intensive care specialist, and Dr Fabio Cuttone, head of pediatric cardiac surgery at the CHUM.
This intervention marked the world's first installation of a third-generation transportable device entirely designed and adapted for infants and children. The UMAC 972, consisting of a medical (intensive care specialist, cardiac surgeon) and paramedical (perfusionist) team, a pioneer in mobile circulatory assistance in the Caribbean archipelago and unique in terms of know-how and experience, played a vital role in the success of this medical treatment.
The infant was admitted to the CHUM pediatric intensive care unit. He received care and was attached to Colibri for five days until his lungs and heart functioned normally. Subsequently, having fully recovered from his bronchiolitis, the child was discharged from hospital and returned to Guadeloupe after 15 days in hospital. He will have to be monitored periodically, like all babies who have been in intensive care. He is now out of danger.

This ground-breaking treatment, the result of cooperation between the Martinique University Hospital, Eurosets, the CTM (Collectivité Territoriale de la Martinique) and European funding from React-UE (Recovery assistance for cohesion and the territories of Europe), finally provides the children of the Caribbean archipelago with a life-saving strategy at the forefront of technology.
Colibri is the world's lightest life-saving device capable of temporarily replacing cardiac and pulmonary functions. It is the only third-generation transportable system entirely designed and adapted to newborns and children.
In addition to adult patients, the device can be used on pediatric or even neonatal patients thanks to a dedicated centrifugal pump. The technology is suitable for use in a variety of therapeutic applications, including extracorporeal cardiopulmonary resuscitation (E-CPR) in cardiac arrest, extracorporeal membrane oxygenation (ECMO) and mechanical circulatory support (MCS).

Equipped with a centrifugal pump with magnetic levitation and a device capable of artificially oxygenating the blood, as well as offering excellent ergonomics, the Colibri is a high-performance circulatory assistance system, ideal in all situations in which intra- and extra-hospital transportability are crucial, including the most extreme rescue operations, such as airborne medical evacuations (by helicopter, passenger airline or military aircraft), scenarios that are common in the Caribbean region.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be crossreferenced with the source-language text, which is the only version of the text intended to have legal effect.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716825866/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p

Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere

Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release

Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta

Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release

We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi

Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release

Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye